Oravax Oral Covid-19 Vaccine: Pill Trial Plans and Results

Facebook ↗WhatsApp ↗

Originally published 2021-03-31.

An Oral COVID-19 Vaccine Candidate Announced in 2021

In March 2021 a new company called Oravax Medical announced that it hoped to begin human trials of a Covid-19 vaccine taken as a capsule rather than an injection. The first trial did start, and in October 2022 Oravax reported early Phase 1 results in 12 healthy volunteers: most produced antibodies and no safety problems were seen. A pill vaccine did not reach the public within a year, as some headlines had suggested, and as far as public records show, no oral Covid-19 vaccine has been authorised for general use.

The idea of swallowing a vaccine instead of rolling up a sleeve is appealing for many reasons. Here is who was behind Oravax, how its vaccine was meant to work, what the trials found, and why oral vaccines are harder to develop than they sound.

Who is behind Oravax

Oravax was announced on 19 March 2021 as a joint venture between two companies. Oramed Pharmaceuticals, based in the US and Israel, had spent years developing a platform called POD for delivering protein drugs by mouth, best known for its work on oral insulin. Premas Biotech, an Indian company, contributed the vaccine design. Oramed was the largest shareholder, with Premas and other investors holding the rest.

At the launch, Oramed's chief executive Nadav Kidron said an oral vaccine "would eliminate several barriers to rapid, widescale distribution". He also argued it could become more valuable if Covid-19 vaccines were ever recommended every year, like flu shots.

How the oral vaccine was designed to work

Most early Covid-19 vaccines, such as those from Pfizer-BioNTech, Moderna and Oxford-AstraZeneca, focused the immune system on one part of the virus: the spike protein it uses to enter cells. Oravax took a different approach.

Its candidate is a virus-like particle (VLP) vaccine. VLPs mimic the outer shell of a virus but contain no genetic material, so they cannot cause infection. Premas's version carries three of the coronavirus's structural proteins: spike, membrane and envelope. The companies argued that targeting three proteins instead of one could offer broader protection as new variants changed the spike.

The capsule is designed to survive the stomach and release the vaccine in the intestine. The gut lining is rich in immune tissue, and an oral vaccine may train the body to produce IgA antibodies, the kind found on mucous membranes in the nose, throat and gut, as well as IgG antibodies in the blood. In a pilot animal study, Oravax said a single oral dose produced both types.

The possible advantages of a vaccine in a capsule

  • No needles. Fear of needles keeps some people from getting vaccinated. Prof. Paul Hunter of the University of East Anglia noted that oral vaccines may help people who are severely needle phobic.
  • Easier distribution. Kidron said the capsules could be shipped in ordinary refrigerators and stored at room temperature, unlike the ultra-cold storage some early mRNA vaccines needed.
  • Self-administration. In principle, people could take a capsule at home without a nurse, which could speed up mass campaigns.
  • Protection where infection starts. Injected vaccines are very good at preventing severe disease but less good at stopping infection in the nose and throat. Mucosal immunity could, in theory, help block transmission.

These were hopes, not proven benefits. Hunter stressed that properly conducted human studies would be needed, adding a caution that applies to most early vaccine news: "don't assume that animal results always translate into human results."

What the Phase 1 trial found

Oravax had aimed to start human trials by June 2021. The first-in-human study eventually tested two oral doses given 21 days apart in up to 24 healthy volunteers, with a low dose in the first group of 12 and a higher dose in the second. Participants were followed for 24 weeks for safety and antibody levels.

On 7 October 2022 the companies released preliminary results from the first 12 volunteers. They said most participants had antibody responses two to six times higher than their starting levels, and that no safety issues were observed. They reported that the trial's safety and immune-response goals were met.

It is important to read this correctly. A Phase 1 trial is designed mainly to check safety and whether the body responds at all. It involves small numbers and cannot show whether a vaccine actually prevents infection or illness. That requires much larger Phase 2 and Phase 3 trials, often with thousands of people.

Why oral vaccines are hard to get right

Oral vaccines are not new. The oral polio vaccine and oral vaccines against rotavirus, cholera and typhoid have been used for decades. But those are mostly live or inactivated whole microbes that naturally infect the gut. Delivering a protein-based vaccine by mouth is much harder, because stomach acid and digestive enzymes are designed to break proteins down.

Oravax was not the first to try for Covid-19. The US company Vaxart reported encouraging animal data for its oral tablet in 2020, but its first human trial produced disappointing antibody responses, a reminder of how animal results can mislead. Other groups, including ImmunityBio and teams at the University of Oxford, explored tablets and nasal sprays as next-generation options.

The wider research field has since shifted towards mucosal vaccines more broadly, including nasal sprays. A few have been approved in some countries, such as China and India, but regulators elsewhere are still waiting for strong evidence that they prevent infection better than injections.

What this means for you

If you are hoping to avoid injections, there is not yet an approved Covid-19 vaccine in pill form available in most countries. The vaccines offered by health services today are injections or, in a few places, nasal sprays, and they remain the main tool for reducing serious illness.

If you are anxious about needles, it is worth knowing that clinics deal with this every day and can help, for example with numbing cream, lying down during the injection or extra time. Talk to a doctor or pharmacist about which vaccines are right for you and whether you are due a booster.

The Oravax story shows how science news tends to work: a bold announcement, a cautious early result and a long road still ahead. Oral vaccines may yet play a role in future pandemics, but they will need to prove themselves in large trials first.

Sources: Oramed, 19 March 2021: Oramed forms a joint venture, Oravax Medical, for novel oral COVID-19 vaccines; ScienceAlert, March 2021: a potential pill-form coronavirus vaccine could soon undergo clinical trials; BioSpace, 7 October 2022: Oravax reports positive preliminary Phase 1 data for its oral Covid-19 vaccine. Comments by Prof. Paul Hunter via ScienceAlert.

COMMENTS